|
experimental hypertension. 1996. V. 18. P. 463-472. Cox W. M., Blount J. P., Crowe P. A. et al. Diabetic patients' alcohol and
quality of life: relationships with prescribed treatment compliance among
older males // Alcoholism. 1996. V. 20. P. 327-331. Cramer J., Vachon L., Desforges C. et al. Dose frequency and dose interval
compliance with multiple antiepileptic medications during a controlled
clinical trial // Epilepsia. 1995. V. 36. P. 1111-1117. Crawford P., Chadwick D. A comparative study of progabide, valproate,
and placebo as add-on therapy in patients with refractory epilepsy //
J. Neurol. Neurosurg. Psychiatry. 1986. V. 49. P. 1251-1257. _ Crowell C. R., Hinson R. E., Siegel S. The role of conditioned drug responses in tolerance to the hypothermic effects of ethanol // Psychopharma-
cology. 1981. V. 73. P. 51-54. Dager S. R, Khan A., Cowley D. et al. Characteristics of placebo response
during long-term treatment of pain disorder // Psychopharmacol. Bull.
1990. V. 26. No. 3. P. 273-278. Dago P. L., Quithin F. M. Role of the placebo response in the treatment of
depressive disorders // CNS Drugs. 1995. V. 4. No. 5. P. 335-340. Davies C, Ralevski E., Kennedy S. H., Neitzert C. The role of personality
factors in the reporting of side effect complaints to moclobemide and
placebo: a study of healthy male and female volunteers // J. Clin.
Psychopharmacol. 1995. V. 15. No. 5. P. 347-352. De Craen A. J. et al. Is there a need to control placebo in placebo controlled
trials? // (Editorial). Heart. 1997. V. 77. P. 95-96. De Deyn P. P. et al. Placebos in clinical practice and research //
J. Med. Ethics. 1996. V. 22. P. 140-146 De Giacomo P., Silvestri A, Pierri G., Lefons E., Corfiati L., Tangorra F.
Research on the effects of psychodrugs on human interaction.
A theoretical/experimental approach // Acta psychiatr. scand. 1986.
V. 74. P. 417-424. Defons E., Corfiati L., Tangorra F. Research on the effects of psychodrugs
on human interaction. A theoretical/experimental approach // Acta
psychiatr. scand. 1986. V. 74. P. 417-424. De Leo D., Rocco P. L., Dello Buono, Valla Barra G. F. Grey mood: grey
colors // Lancet. 1989, Sept. 2. P. 573-574. Del Boca F. K., Kranzler H. R., Brown J. et al. Assessment of medication
compliance in alcoholics through UV light detection of a riboflavin
trascer // Alcoholism. 1996. V. 20. P. 1412-1417. Demyttenaere K. Compliance during treatment with antidepressants //
J. Eof Affective Disorders. 1997. V. 43. No. 1. P. 27-40. DiMascio A., Barrett J. Comparative effects of oxazepam in «high» and
«low» anxious student volunteers // Psychosomatics. 1965. V. 6.
P. 298-302. DiMascio A., Rinkel M. Personality and drugs. «Specific» and «Non-Spe-
cific» Influences on Drug Action // Specific and Non-Specific Factors
in Psychopharmacology / Ed. M. Rinkel. 1963. N. Y.: Philosophical
Library. P. 130-140. Dobrilla G., Scarpignato С Placebo and placebo effect: their impact on the
evaluation of drug response in patients // Digestive Diseases. 1994.
V. 12. No. 6. P. 368-377.
Double D. B. Placebo mania. Placebo controlled trials are needed to provide data on effectiveness of active treatment (letter) // Brit. Med. J.
1996. V. 313. No. 7063. P. 1008-1009.
212
Плацебо и терапия
Downing R. W., Rickets К., King L., Rickets L. A. Factors influencing dosage deviation and attrition in placebo treated neurotic outpatients // J. Psychiat. Res. 1975. V. 12. P. 239-256.
Dow son D. I., Lewith G. Т., Machin D. The effects of acupuncture versus placebo in the treatment of headache // Pain. 1985. V. 21. P. 35-42.
Doyle A. E. Response to placebo treatment in hypertension. Hypertension. 1983. V. 5. No. 5. P. 1113-1114.
Drory V. E., Korczyn A. D. Apparent placebo effect in epilepsy // New Trends Clin. Psychopharmacol. 1991. V. 5. No. 2. P. 49-56. Цит. по РЖ 04. Биология. 1992. 4. Т. З. 199.
Duburg G. O. Compliance therapy in psychotic patients. Authors are wrong to compare treatment with no treatment // Brit. Med. J. 1996. V. 312. P. 1302.
Eastman C. /. What the placebo literature can tell us about light therapy for SAD // Psychopharmacol. Bull. 1990. V. 26. P. 495-504.
Elizaga J., Friedland J. S. Monitoring compliance with antituberculosis treatment by detection of isoniazid in urine // Lancet. 1997. V. 350. No. 9086. P. 1225-1226.
Ellgring H. Nonverbal expression of psychological states in psychiatric patients // Eur. Arch. Psychiatr. Neurol. Sci. 1986. V. 236. P. 31-34.
Epstein J. B. Understanding placebos in dentistry // J. of Amer. Dental Ass. 1984. V. 109. No. 1. P. 71-74.
Ernst E., Herxheimer A. The power of placebo — Let's use it to help us as much as possible // Brit. Med. J. 1996. V. 313. No. 7072. Dec. 21. P. 1569-1570.
Ernst E., Resch K. L. Concept of true and perceived placebo effects // Brit. Med. J. 1995. V. 311. No. 7004. P. 551-553.
Esse S. Placebo reactions and spontaneous rhythms in psychotherapy // Arch. Gen. Psychiatry. 1964. V. 10. No. 5. P. 497-505.
Evans L., Spelman M. The problem of non-compliance with drug therapy // Drugs. 1983. V. 25. P. 63-66.
Fedder D. O. Managing medication and compliance: physician-pharmacist-patient interaction // J. Amer. Geriat. Soc. 1982. V. 30. S. 113.
Feldman D. E. Non-drug parameters of psychopharmacology. The role of the physician // specific and non-specific factors in psychopharmacology / Ed. M. Rinkel. N. Y.: Philosophical Library, 1963. P. 149-158.
Fenton W. S., Blyler C. R., Heinssen R. K. Determinants of medication compliance in schizophrenia: empirical and clinical findings // Schizophrenia Bull. 1997. V. 23. No. 4. P. 637-652.
Fillmore M., Vogel-Sprott M. Expected effect of caffeine on motor performance predicts the type of response to placebo // Psychopharmacology. 1992. V. 106. P. 209-214.
Fischer H. K., Dlin В. Af. The dynamics of placebo therapy: a clinical study. Amer. J. Med. Sci. 1956. V. 232. P. 504-512.
Folli G. et al. Placebo effect in the treatment of angina pectoris // Acta Cardiologica. 1978. V. 33. N. 4. P. 231-239.
Fossey Af. D.. Lydiard R. B. Placebo response in patients with anxiety disorders // The treatment of anxiety. Handbook of anxiety / Eds. R. Noyes, M. Roth, G. Burrows. Amsterdam: Elsevier, 1990. P. 27-56.
Frank D. R. Psychological theories of the effects of placebos with special consideration for the contribution theory // Pharmacopsychiatry. 1986. V. 19. P. 337-338.
Frank J. D., Gliedman L. #., Imber S. D., Nash E. H., Stone A. R. Why patients leave psychotherapy // AMA Arch. Neurol. Psychiat. 1957. V. 77. P. 283-
Gartner M. A. Selected personality differences between placebo reactors and non-reactors // J. Amer. Osteopath. Ass. 1961. V. 60. P. 377-378.
Литература 213
Gauler Т. С, Weihrauch Т. R. Placebo — an effective and harmless drug? // Naunyn-Schmiedeberg's Arhiv of Pharmacology. 1996. V. 354. Suppl. 1 (Abstracts of the Autumn Meeting of the Deutsche Gesellschaft fiir experimentalle und klinische Pharmakologie und Toxikologie. P. 24.
Geerts E., Bouhuys N. Multi-level prediction of short-term outcome of depression: non-verbal interpersonal processes, cognitions and personality traits // Psychiatry Research. 1998. V. 79. No. 1. P. 59-73.
Gillin J. C. et al. No antidepressant effects of biperiden compared with placebo in depression: a double-blind 6-week clinical trial // Psychiatric Research. 1995. V. 58. No. 2. P. 99-106.
Girvin В., Byrne A, Kiny D. J., Wilson-Davis K., Johnston G. D. An assessment of erythrocyte lithium concentration as a measure of patient compliance // Human Psychopharmacology — clinical and experimental. 1996. V. 11. No. 6. P. 491-496.
Glassman J. N. The psychodynamics of prescribing and receiving medication // Psychiatric Times. 1998, May. P. 33-35.
Glaudin V., Smith W. Т., Ferguson J. M. et al. Discriminating placebo and drug in generalized anxiety disorder (GAD) trials: single versus multiple clinical raters // Psychopharmacol. Bull. 1994. V. 30. P. 101.
Gliedman L. H., Nash E. H., Imber S. D. et al. Reduction of symptoms by pharmacologically inert substances and by short-term psychotherapy // Arch. Neurol. Psychiatry. 1958. V. 79. P. 345-351.
Gotzsche P. C. Placebo effects — Concept of placebo should be discarded // Brit. Med. J. 1995. Vol. 311. No. 7020. Dec. 16. P. 1640.
Gracely R. H., Dubner R., Wolskee P. J. et al. Placebo and naloxone can alter post-surgical pain by separate mechanisms // Nature. 1983. V. 306. P. 264-265.
Gray G., Flynn P. A survey of placebo use in general hospital // General Hospital Psychiatry. 1981. V. 3. No. 3. P. 199-203.
Greenberg R. P., Fischer S. Examining antidepressant effectiveness: findings, ambiguities, and some vexing puzzles. The Limits of Biological Treatments for Psychological Distress: Comparisons wirh Psychotherapy and Placebo / Eds. S. Fischer, R. P. Greenberg Lawrence Erl-baum Associates. Hillsdale, N. Y., 1989. P. 1-37.
Gross F. Placebo — das universalle Medikament. Mainz. MPS. 1984.134 S.
Grunbaum A. The placebo concept in medicine and psychiatry // Psychol. Med. 1986. V. 16. P. 19-38.
Haas H. et al. Das Placebo-Problem // Fortschritte der Arzneimittelfor-schung / Ed. E. Jucker. 1959. Bd. 1. S. 279.
Hafer H. Angst als Chance und als Krankheit // Fundamenta Psychiat-rica. 1987. V. 1.
Haimovic I. C, Beresford H. R. Dexamethasone is not superior to placebo for treating lumbosacral radicular pain // Neurology. 1986. V. 36. No. 12. P. 1593-1594.
Harrison W. et al. Is loss of antidepressant effect during continuation therapy related to placebo effect? // Psychopharmacol. Bull. 1988. V. 24. P. 9-13.
Hart F. D. Placebos used not to be used in studies // Brit. Med. J. 1995. V. 311. No. 7020. P. 1641.
Hart noil R. Non-pharmacological factors in drug abuse // Behavioral Pharmacol. 1990. V. 1. P. 375-384.
Hayes-Bautista D. F. Modifying the treatment: patient compliance, patient control and medical care // Soc. Sci. Med. 1976. V. 10. P. 233-235.
Heeg W., Deutsche K. F., Deutsche E. The placebo effect // Eur. J. Nuclear Medicine. 1997. V. 24. P. 1433-1444.
Henlnger G., DiMascio A., Klerman G. L. Personality factors in variability of response to phenothiazines // Amer. J. Psychiatry. 1965. V. 121. P. 1091-1094.
214
Плацебо и терапия
Негг A. The role of opioid peptides in placebo-induced effects // Phar-macopsychiat. 1986. V. 19. P. 339-340.
Hesbacher P. Т., Rickels K., Hutchison I. et al. Setting, patient, and doctor effects on drug response in neurotic patients: II Differential improvement // Psychopharmacologia. 1970. V. 18. P. 209-226.
Hese R. Т., Chmurska M. Porownanie wynikow leczenia chorych na nerv-ice lekami psychotropoowymi i placebo // Psychiatria Polska. 1982. V. 16. N. 4. P. 267-272.
Heszen-Klemens I. Patients' noncompliance and how doctors manage this // Clin. Sci. Med. 1987. V. 24. No. 5. P. 409-416.
Hill M. N.. Niller N. Y. Compliance enhancement: A call for multidisci-plinary team approaches // Circulation. 1996. V. 93. P. 4-6.
Hippius H. et al. (Eds.) Das Placebo-Problem. Stuttgart: Fischer-Verlag, 1986. S. 151
Hollon S. D., Beck A. T. Psychotherapy and drug therapy: comparisons and combinations // Handbook of Psychotherapy and behavior change: an empirical analysis / Eds. S. L. Garfield, A. E. Bergin. 2nd edition. N. Y.: Wiley, 1978. P. 64-64.
Hollon S. D., De Rubeis R. J. Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-pscyhotherapy comparative trials // Psychological Bull. 1981. V. 90. P. 467-477.
Home J. A., Reyner t. A. Counteracting driver sleepness: Effects of napping, caffeine, and placebo // Psychophysiology. 1996. V. 33. No. 8. P. 306-310.
Hubin P., Servais J. Etude typologique du placebo-reacteur // Psychopharmacologia. 1965. V. 7. No. 4. P. 235-255.
Hyland J. Integrating psychotherapy and pharmacotherapy // Bull. Men-ninger Clinic. 1991. V. 55. P. 205-215
Illhardt F. J. Placebo und Ethik // Z. Allgem. Med. 1988. Bd. 64. S. 279-283.
Isohanni M. Psychotropic drugs in the therapeutic community // Psychiatria fennica. Intern. Edition. 1982. P. 175-186.
Jacobs K. W., Nordan F. M. Classification of placebo drugs: effect of color // Perceptual and Motor Skills. 1979. V. 49. P. 367-372.
Janke W. Consistency of response to placebo with different instructions // Pharmacopsychiat. 1986. V. 19. P. 345-346.
Janke W. Untersuchungen zur Placeboreaktivitflt: Vorheragbarkeit der Reaktion gesunder Personen auf Placebo mit Stimulans-Instruktion. «Das Placebo-Problem» / Herausgegeben H. Hippius. et al. Stuttgart; N. Y.: Fischer Verlag, 1986. S. 151-171.
Jensen M. P., Karoly P. Motivation and expectancy factors in symptom perception: a laboratory study of the placebo effect // Psychosomatic medicine. 1991. V. 53. P. 144-152.
Joyce C. R. B. The personality of healthy reactors and nonreactors to dummy treatment // Neuropsychopharmacology / Eds. P. B. Bradley, P. Deniker P, С N. Radouco-Thomas. Y.: Elsevier, 1959. P. 448-452.
Karasu T. Psychotherapy and pharmacotherapy: toward an integrated model // Amer. J. Psychotherapy. 1982. V. 139. P. 1102-113.
Karson C. N. et al. Clonazepam treatment of chronic schizophrenia: negative results in a double-blind placebo-controlled trial // Amer. J. Psychiatry. 1982. V. 139. No. 12. P. 1627-1628/
Khan A. et al. Chronicity of depressive episode in relation to antidepres-sant-placebo response // Neuropsychopharmacology. 1991. V. 4. No. 2. P. 125-130.
Kienle G. S. et al. Placebo effect and placebo concept: a critical methodological and conceptual analysis of reports on the magnitude of the placebo effect // Altern. Ther. Health Med. 1996. V. 2. P. 39-54.
Kirsch I. Response expectancy as a determinant of experience and behavior // American Psychologist. 1985. V. 40. P. 1189-1202.
Литература 215
Kirsch I., Weixel L. J. Double-blind versus deceptive administration of a placebo // Behavioral Neuroscience. 1988. V. 102. P. 319-323.
Klerman G. L. Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology // Psychopharmacol. Bull. 1986. V. 22. No. 1. P. 25-29.
Klerman G. L., Di Mascio A., Rinkel M., Greenblatt M. The influence of specific personality patterns on the reactions to phrenotropic drugs // Biological Psychiatry / Ed. J. Masserman. N. Y.: Grune, 1959. V. 1. P. 224-226.
Kroneerg G. Placebotherapie. XIII. Medicenale. Iserlohn. 1982. 468 s.
Kuhn R. bber die Behandlung depressiver Zustande mit einem iminodiben-zylderivat (G 22355) // Schweiz. Med. Wschr. 1957. Bd. 87. S. 1135.
Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride) // Amer. J. Psychiatry. 1958. V. 115. P. 459-464.
Kuhn R. History and future of antidepressants // The Rise of Psychopharmacology / Ed. T. A. Ban, D. Healy, E. Shorter. Budapest: Animula, 1998. P. 76-77.
Kurland A. A. The drug placebo: its psychodynamic and conditioned reflex action // Behav. Sci. 1957. V. 2. P. 101-110.
Kuschinsky G. Wirkvmgen und Indikationen von Placebo // Dtsch. Arzte-bl. 1975. Bd. 72. S. 663-666.
Kashner M. G., Sher K. J. Anxiety and drinking behavior: moderating effects of alcohol-related expectancies // Pharmacol. Biochem. Behav. 1992. V. 16. Suppl. P. 378.
Lange H. U. Zur Praxis der Plazebobehandlung in einer psychiatrischen Klinik // Psychiatrische Praxis. 1981. Bd. 8. Nr. 4. S. 147-151.
Langer G. Placebo: Jenseits von «Schein» und «Storgrosse» // Wien. klin. Wochenschr. 1987. Bd. 99. Suppl. 175. S. 13/
Lapin I. P. Kynurenines as probable participants of depression // Pharma-kopsychiatrie-Neuropsychopharmakologie. 1973. V. 6. P. 273-279.
Lapin I. P. Only controls: effect of handling, sham injection and intraperito-neal injection of saline on behavior of mice in an elevated plus-maze // J. Pharmacol, and Toxicol. Methods. 1995. V. 34. No. 2. P. 73-77.
Lapin I. P. Lowered serotonin uptake in blood platelets (SU) in alcoholic patients. Is it specific for alcoholism? Does it appear before or during the disease? // Alcohol and alcoholism. 1997. V. 32. P. 383.
Lapin I. P. Three foundation stones of the laboratory of psychopharmacology // The Rise of Psychopharmacology and the story of CINP / Ed. by T. A. Ban, D. Healy, E. Shorter. Budapest: Animula, 1998. P. 323-329.
Lapin I. P., Oxenkrug G. F. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect // Lancet. 1969. V. 1. P. 132-136.
Lasagna L. Placebos // Sci. Amer. 1955. V. 193. P. 68-71.
Lasagna L. The relation of drug-induced changes to personality // Specific and Non-specific Factors in Psychopharmacology / Ed. M. Rinkel. N. Y.: Philosophical Library, 1963. P. 114-129.
Lasagna L., Laties V. G., Dohan L. L. Further studies on the «pharmacology» of placebo administration // J. Clin. Invest. 1958. V. 37. P. 533-537.
Laurinaitis E. Ethical issues in the post-soviet psychiatry and psychotherapy — implications for research // The Synthesis between Psychopharmacology and Psychotherapy. Abstracts of the WPA Thematic Conference (Jerusalem, Israel, Nov. 16-21, 1997). P. 12.
Lawrence D. R. Clinical pharmacology // Edinburgh; London; N. Y.: Churchill Livingstone, 1973. 356 p.
Lazarus R. S., Folkman S. Coping and adaptation. The Handbook of Behavioral Medicine / Ed. W. D. Gentry. N. Y.: Guilford, 1984. P. 282-325.
216
Плацебо и терапия
Leber P. The placebo control in clinical trials (a view from the FDA) // Psychopharm. Bull. 1986. V. 22. No. 1. P. 30-32.
Leder S., Bekarewicz В., Bigo В., Kosewska A. Proby analyzy czynnikow krsztaltujancych efekt placebo // Biul. Inst. Psyhoneurol (Warszawa). 1972. V. 3. S. 87-95.
Lehmann E. D., Hopkins K. D., Gosling R. G. Multiple definitions of «compliance» // Clinical Science. 1996. V. 90. P. 433-435.
Lehmann H. E., Knight D. A. Placebo proneness and placebo resistance of different psychological functions // Psychiat. Quat. 1960. V. 3. P. 505-516.
Leonhard K. Der menschliche Ausdruck // Johann Ambrosius Barth. Leipzig, 1968. 320 s.
Leslie A. Ethics and practice of placebo therapy // Amer. J. Med. 1954. V. 16. P. 854-860.
Levine J. D., Gorden N. C, Fields H. L. The mechanism of placebo analgesia // Lancet. 1978. II. P. 654.
Lindahl O., Lindwall L. Is all therapy just a placebo effect? // Metamedi-cine. 1982. V. 3. P. 255.
Lipman R. S., Rickels K., Uhnlenhutk E. H., Park L. C, Fisher S. Neurotics who fail to take their drugs // Brit. J. Psychiat. 1965. V. 111. P. 1043.
Lowinger P., Dobie S. A study of placebo response rates // Arch. Gen. Psychiatry. 1969. V. 20. P. 84-88.
Luscher M. Color test Translated and edited by J. A. Scott. N. Y.: Pocket Book ed., 1971. 187 p.
Luscher M. Farb Form Test. Luzern: Color-Test-Verlag. 1979. 93 s.
Luscher M. The psychological influence of capsule colours on the therapeutic effect of a drug // Carsugel News Sheet. BAS. 127. N. Y., 1984. P. 1-8.
Luscher M. Die Luscher-Farben zur Personlichkeitbeurteilung und Konf-liktlosung. Mbnchen: Mosaik, 1989. 159 s.
Luther E. (Ed.) Ethik in der Medizin. Berlin: VEB Verlag Volk und Ge-sundheit, 1986. S. 52.
Lynoe N., Mattson В., Sandlund M. The attitudes of patients and physicians towards placebo treatment — a comparative study // Social Science and Medicine. 1993. V. 36. No. 6. P. 767-774.
Lyons D. Benefits of placebos // Nature. 1995. V. 378. No. 6553. P. 125.
Madeiska N. Malarstwo i schizophrenia. Krakow: Wydawnictwo literack-ie, 1975. 137 p.
Madsen K., MacLean D. A, Kiens В., Christensen D. Effects of glucose, glucose plus branched-chain aminoacids, or placebo on bike performance over 100 km // J. of Applied Physiol. 1996. Vol. 81. No. 6. P. 2644-2695.
|
